Press releases

April 12, 2023

Overland ADCT BioPharma Announces Pivotal Phase 2 Clinical Trial in China Evaluating ZYNLONTA® for DLBCL Achieves Primary Objective

November 02, 2022

Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia

July 11, 2022

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial

March 01, 2022

Overland Pharmaceuticals Appoints Dr. Xun Liu as Chief Technology Officer

January 18, 2022

Overland Pharmaceuticals Appoints Ed Zhang as Chief Executive Officer and Welcomes Industry Leaders John Maraganore and Peter Ho as Strategic Advisors

September 29, 2021

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma

August 02, 2021

Overland Pharmaceuticals Appoints Roger Luo, Ph.D. as Chief Development Officer

June 21, 2021

Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer

April 06, 2021

Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer

December 15, 2020

Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies

December 14, 2020

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore

December 09, 2020

Overland Pharmaceuticals Debuts as Premier Biopharmaceutical Company to Bring Innovative Medicines to Asia and Worldwide